-+ 0.00%
-+ 0.00%
-+ 0.00%

BrainsWay Announces Premera Blue Cross Blue Shield Adopts New Final Medical Policy To Treat Moderate To Severe Major Depressive Disorder With Brainsway's Accelerated SWIFT Deep TMS Protocol

Benzinga·01/07/2026 12:38:11
Listen to the news

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced that Premera Blue Cross Blue Shield®, a company with over 2.8 million covered lives serving Alaska and Washington state, has adopted a new final medical policy which, among other developments, expands coverage to include patients ages 15 and older with moderate to severe major depressive disorder (MDD) treated with BrainsWay's accelerated SWIFT™ (Short-course with Intrinsic Field Targeting) Deep TMS™ protocol.